Dicerna Pharmaceuticals, Inc. (DRNA) Given Consensus Recommendation of “Hold” by Brokerages
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has received a consensus rating of “Hold” from the eight analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $8.33.
A number of analysts have recently commented on DRNA shares. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 23rd. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, July 22nd. Finally, Chardan Capital restated a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th.
Dicerna Pharmaceuticals (NASDAQ DRNA) traded up 3.51% during midday trading on Friday, hitting $3.54. The stock had a trading volume of 76,284 shares. The firm’s market cap is $73.79 million. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $6.10. The stock has a 50-day moving average of $3.44 and a 200-day moving average of $3.18.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.54. The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.08 million. Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. The business’s revenue for the quarter was up 2400.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.75) earnings per share. Analysts forecast that Dicerna Pharmaceuticals will post ($2.70) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/dicerna-pharmaceuticals-inc-drna-given-consensus-recommendation-of-hold-by-brokerages/1550916.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp raised its holdings in Dicerna Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 2,094 shares in the last quarter. Bourgeon Capital Management LLC raised its holdings in Dicerna Pharmaceuticals by 188.9% during the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 25,500 shares in the last quarter. Paloma Partners Management Co raised its holdings in Dicerna Pharmaceuticals by 49.7% during the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock worth $544,000 after acquiring an additional 53,131 shares in the last quarter. Sabby Management LLC raised its holdings in Dicerna Pharmaceuticals by 100.0% during the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock worth $680,000 after acquiring an additional 100,000 shares in the last quarter. Finally, UBS Group AG raised its holdings in Dicerna Pharmaceuticals by 0.6% during the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after acquiring an additional 1,599 shares in the last quarter. Institutional investors and hedge funds own 55.54% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.